ORXO.F Stock Overview
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.50 |
| 52 Week High | kr1.95 |
| 52 Week Low | kr1.04 |
| Beta | 0.58 |
| 1 Month Change | -0.33% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORXO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.0% | 0.3% |
| 1Y | n/a | 12.0% | 24.2% |
Return vs Industry: Insufficient data to determine how ORXO.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORXO.F performed against the US Market.
Price Volatility
| ORXO.F volatility | |
|---|---|
| ORXO.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ORXO.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORXO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 116 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORXO.F fundamental statistics | |
|---|---|
| Market cap | US$54.38m |
| Earnings (TTM) | -US$11.77m |
| Revenue (TTM) | US$58.62m |
0.9x
P/S Ratio-4.5x
P/E RatioIs ORXO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORXO.F income statement (TTM) | |
|---|---|
| Revenue | kr638.80m |
| Cost of Revenue | kr88.90m |
| Gross Profit | kr549.90m |
| Other Expenses | kr678.20m |
| Earnings | -kr128.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -3.72 |
| Gross Margin | 86.08% |
| Net Profit Margin | -20.08% |
| Debt/Equity Ratio | 761.3% |
How did ORXO.F perform over the long term?
See historical performance and comparison